Phase III
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
AstraZeneca’s Farxiga (dapagliflozin) dramatically prolonged survival in patients with chronic kidney disease in a Phase III clinical trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 28, 2020.
The trials were identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies that evaluated tapinarof cream, 1% in adults with plaque psoriasis.
BMS announced that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care (BSC) compared to conventional care, did not meet the primary endpoint of overall survival in relapsed or refractory acute myeloid leukemia (r/r AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Specifically, the trial of Spartalizumab did not meet the primary endpoint of investigator-assessed progression-free survival.
PRESS RELEASES